Scholar Rock (SRRK) Director Akkaraju Buys $6.1M of Stock

Srinivas Akkaraju, a Director at Scholar Rock Holding Corporation (SRRK), bought 146,970 shares on October 26, 2026, for about $6.1 million. This purchase increased his total holdings to 723,020 shares, marking a 25.5% rise in his stake. The transaction was reported in a Form 4 filing with the SEC.

SRRK Scholar Rock Holding Corporation

$41.71 ▼ -2.55% year to date

1M 3M YTD

Daily close · Oct 26, 2026

What Changed in Akkaraju's Scholar Rock Position

Akkaraju's latest buy came at a price of $41.59 per share, with the stock closing at $41.71 on the same day. This move reflects his continued confidence in the company as he increases his ownership.

Other Institutional Activity in Scholar Rock

Several institutional investors have also adjusted their positions in Scholar Rock. Driehaus Capital Management reduced its stake by 32,644 shares, holding 1,920,233 shares valued at about $100.5 million. Siren, L.L.C. trimmed its holdings, now owning 9,575,013 shares worth approximately $406.8 million, a decrease of 1,250,327 shares. Meanwhile, Samsara BioCapital, LLC maintained its position with 6,897,652 shares valued at about $293.1 million, while Orbis Allan Gray Ltd increased its stake by 1,753,517 shares, ending with 5,933,533 shares worth about $252.1 million.

Scholar Rock Holding Corporation Stock Up 1.9%

Scholar Rock shares closed at $41.71 on October 26, 2026, and have recently traded around $42.49 as of October 28, 2026. This represents an increase of about 1.9% since the trade. However, the stock is still below its 50-day and 200-day moving averages, indicating some challenges in gaining momentum. The current trading price is about 39.7% lower than the mean analyst target price of $70.44, suggesting potential for growth.

Recent Earnings

Scholar Rock has no meaningful earnings data to report, as it has been operating at a loss, with a trailing twelve months (TTM) earnings per share (EPS) of -$3.32. The next earnings report is expected on November 10, 2026, which could provide further insights into its financial health.

Insider Buying and Selling at Scholar Rock Holding Corporation

Since July 1, 2026, several insiders have sold shares. Michael Z. Gilman, Kristina M. Burow, Jeffrey S. Flier, and Joshua Reed, all Directors, sold shares totaling 12,200 shares combined, but did not make any purchases during this time.

Analysts Set New Price Targets

On September 15, 2026, multiple analysts maintained their ratings on Scholar Rock. Evercore ISI Group kept its rating at Outperform with a target of $72.00, while Piper Sandler rated it Overweight with a target of $75.00. Jefferies maintained a Buy rating with a target of $65.00. These ratings reflect a strong consensus among analysts, with an overall recommendation of Strong Buy and a mean price target of $70.44.

About Scholar Rock

Scholar Rock Holding Corporation is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases. The company aims to improve the lives of patients through its innovative therapies.

Bottom Line

Akkaraju's significant purchase signals confidence in Scholar Rock's future. Investors will be watching the upcoming earnings report on November 10, 2026, for more insights into the company's performance. Additionally, the stock's current valuation compared to analyst targets suggests potential opportunities for growth.